Vitruvia Medical AG
· ISIN: CH0461931419
· EQS - adhoc news
Year End results as of December 31,2024
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News Vitruvia Medical AG
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
03 May 2025 07:57AM
Year End results as of December 31,2024
Vitruvia Medical AG: Year End results as of December 31, 2024
Anglikon, May 3, 2025: Vitruvia Medical AG achieved a result after taxes of CHF -173’775.93 in the past year 2024 compared to CHF -243’896.10 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenue of EUR 2’108’483.00 (previous year EUR 1,757,724.00 /...
Vitruvia Medical AG
25 July 2024 09:58PM
Half yearly results as per June 30th, 2024
Vitruvia Medical AG half-year results as of June 30, 2024
Vitruvia Medical AG achieves results as expected in the first half of 2024. The Board of Directors confirms the forecast for the year as a whole.
Vitruvia Medical AG is on target for the first six months of 2024. The result amounted to CHF -52,968.06 compared to CHF -150,464.24 in the p...
Vitruvia Medical AG
01 May 2024 08:36AM
Year End results as of December 31, 2023
Vitruvia Medical AG: Year End results as of December 31, 2023
Anglikon, May 1st , 2024: Vitruvia Medical AG achieved a result after taxes of CHF -243,864.40 in the past year 2023 compared to CHF -1,095,349.38 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenue of EUR 1,7575,724.00 (previous year: EUR 1,525,529.00)...
Vitruvia Medical AG
01 May 2024 08:36AM
Year End results as of December 31, 2023
Vitruvia Medical AG: Year End results as of December 31, 2023
Anglikon, May 1st , 2024: Vitruvia Medical AG achieved a result after taxes of CHF -243,864.40 in the past year 2023 compared to CHF -1,095,349.38 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenue of EUR 1,7575,724.00 (previous year: EUR 1,525,529.00)...
Vitruvia Medical AG
29 September 2023 01:15PM
Consolidated interim results as per June 30th,2023
Consolidated interim results as per June 30th,2023
Vitruvia Medical AG achieves results as expected in the first half of 2023. The Board of Directors confirms the guidance for the full year.
Vitruvia Medical AG is on target in the first six months of 2023. The company generated consolidated revenues of approximately EUR 855,000.00 in the first h...
Vitruvia Medical AG
29 September 2023 12:15PM
Consolidated interim results as per June 30th,2023
Consolidated interim results as per June 30th,2023
Vitruvia Medical AG achieves results as expected in the first half of 2023. The Board of Directors confirms the guidance for the full year.
Vitruvia Medical AG is on target in the first six months of 2023. The company generated consolidated revenues of approximately EUR 855,000.00 in the first h...
Vitruvia Medical AG
28 July 2023 08:17AM
Vitruvia Medical AG: Shareholders approved all proposals at the Annual General Meeting of Shareholders
Vitruvia Medical AG announces that the Company's shareholders approved all proposals on the agenda of the Annual General Meeting held in Baden (AG) on July 26, 2023. A total of 1,110,582 voting shares, representing 44.2% of the total share capital, were represented at this Annual General Meeting.
Markus A. Bertschin, Chairman of the Board of Di...
Vitruvia Medical AG
28 July 2023 08:17AM
Shareholders approved all proposals at the Annual General Meeting of Shareholders
Vitruvia Medical AG announces that the Company's shareholders approved all proposals on the agenda of the Annual General Meeting held in Baden (AG) on July 26, 2023. A total of 1,110,582 voting shares, representing 44.2% of the total share capital, were represented at this Annual General Meeting.
Markus A. Bertschin, Chairman of the Board of Di...
Vitruvia Medical AG
25 June 2023 09:59AM
Annual results as of 31.12.2022 and outlook 2023
Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023
Anglikon, June 25, 2023: Vitruvia Medical AG reported net income after taxes of CHF -1,095,349.38 for the year ended December 31, 2022, compared to CHF -8,002,497.53 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenues of EUR 1,525,529.-- and op...
Vitruvia Medical AG
25 June 2023 09:59AM
Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023
Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023
Anglikon, June 25, 2023: Vitruvia Medical AG reported net income after taxes of CHF -1,095,349.38 for the year ended December 31, 2022, compared to CHF -8,002,497.53 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenues of EUR 1,525,529.-- and op...
Vitruvia Medical AG
27 March 2023 11:34AM
auhtorised capital increase
Ad Hoc Announcement
Anglikon, 27 March 2023: Vitruvia Medical AG has carried out an authorised capital increase as of today. Receivables in the amount of CHF 1'680'817.50 were offset, for which 672'327 registered shares at CHF 1.00 each were issued. The issue price was CHF 2.50 per registered share. The share capital of Vitruvia Medical AG now am...
Vitruvia Medical AG
27 March 2023 11:34AM
Vitruvia Medical AG: auhtorised capital increase
Ad Hoc Announcement
Anglikon, 27 March 2023: Vitruvia Medical AG has carried out an authorised capital increase as of today. Receivables in the amount of CHF 1'680'817.50 were offset, for which 672'327 registered shares at CHF 1.00 each were issued. The issue price was CHF 2.50 per registered share. The share capital of Vitruvia Medical AG now am...
Vitruvia Medical AG
19 January 2023 11:47AM
Cooperation with TRES MEDICO, Malaysia
Anglikon, January 19, 2023:
New cooperation of LT technologies Gmbh & Co. KG with TRES MEDICO, Malaysia
Our affiliate LT technologies has entered a cooperation in the field of repair service with the Malaysian company TRES MEDICO, a 100% subsidiary of HG Medic Sdn Bhd, Malaysia.
As one of the few German companies in the repair service of sur...
Vitruvia Medical AG
26 November 2022 04:43PM
Vitruvia Medical AG: Issue of 6.00% Convertibel Bond 2022-2025
Convertible bond Vitruvia Medical AG ("Private Placement") 6.00% 2022-2025
By resolution of the Board of Directors, Vitruvia Medical AG has resolved to issue a convertible bond ("Private Placement") of CHF 2.2 million at an interest rate of 6.00% p.a. and a term of 3 years. The issue price is set at 100% and the conversion price is EUR 2...
Vitruvia Medical AG
26 November 2022 04:43PM
Issue of 6.00% Convertibel Bond 2022-2025
Convertible bond Vitruvia Medical AG ("Private Placement") 6.00% 2022-2025
By resolution of the Board of Directors, Vitruvia Medical AG has resolved to issue a convertible bond ("Private Placement") of CHF 2.2 million at an interest rate of 6.00% p.a. and a term of 3 years. The issue price is set at 100% and the conversion price is EUR 2...
Vitruvia Medical AG
30 September 2022 09:52AM
Successful certification of FFP 2 masks with medical approval of LT technologies
Successful certification of FFP 2 masks with medical approval
of LT technologies
LT technologies has successfully passed the certification of the FFP2 masks with medical approval.
The TechMed Mask is a particle-filtering half mask for protection against aerosols, including viruses and particles. It is excellent for use in infect...
Vitruvia Medical AG
30 September 2022 09:52AM
Vitruvia Medical AG: Successful certification of FFP 2 masks with medical approval of LT technologies
Successful certification of FFP 2 masks with medical approval
of LT technologies
LT technologies has successfully passed the certification of the FFP2 masks with medical approval.
The TechMed Mask is a particle-filtering half mask for protection against aerosols, including viruses and particles. It is excellent for use in infect...
Vitruvia Medical AG
30 September 2022 09:30AM
Half-year results as of 30.6.2022 incl. half-year report
Vitruvia Medical AG: Half-year results as of 30.6.2022 incl. half-year report
Anglikon, 30 September 2022: Vitruvia Medical AG generated revenues of approximately EUR 0.66 million in the first six months of the financial year. Earnings before interest, taxes, depreciation and amortisation amounted to EUR 21,077.00. It should be noted that the disp...
Vitruvia Medical AG
30 September 2022 09:30AM
Vitruvia Medical AG: Half-year results as of 30.6.2022 incl. half-year report
Vitruvia Medical AG: Half-year results as of 30.6.2022 incl. half-year report
Anglikon, 30 September 2022: Vitruvia Medical AG generated revenues of approximately EUR 0.66 million in the first six months of the financial year. Earnings before interest, taxes, depreciation and amortisation amounted to EUR 21,077.00. It should be noted that the disp...
Vitruvia Medical AG
28 July 2021 10:00AM
Vitruvia Medical AG: Successful certification for the reprocessing of 'critical C' devices - Vitruvia Medical now also providing circular systems for highest risk-level medical devices
Successful certification for the reprocessing of "critical C" devices - Vitruvia Medical now also providing circular systems for highest risk-level medical devicesSchönebeck, July 28, 2021 Vitruvia Medical, which specializes in circular systems for highly complex medical products, particularly robot-assisted surgery, now also holds
DIN EN ISO 13485...
Vitruvia Medical AG
01 July 2021 10:33AM
Vitruvia Medical's first Circular Clinic Supply Center for robotic instruments goes live with first customers
Vitruvia Medical's first Circular Clinic Supply Center for robotic instruments goes live with first customers
Schönebeck, July 1, 2021 - Vitruvia is the first European service provider to specialize in circular systems for highly complex medical devices. On a site of 2,000 sqm located in Schönebeck, near Magdeburg, Vitruvia has now opened a Circul...
Vitruvia Medical AG
More Vitruvia Medical AG related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 0 | - | - | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN